Clinical Trial

Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This trial aims to demonstrate the feasibility of this approach to reliably generate product and to safely administer the product to patients who have B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2022-03-08; most recent amendment 2025-01-10.
Status change: Not Yet Recruiting → Recruiting 2022-08-10
Trial Details
NCT Number NCT05281809
Lead Sponsor John Lister
Collaborators: Lentigen Technology, Inc., Miltenyi Biotec, Inc., Allegheny Health Network
Conditions B-Cell Lymphoma, B Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Lymphoplasmacytic Lymphoma, Chronic Lymphocytic Leukemia +1 more
Enrollment 30 participants
Start Date 2022-04-19
Primary Completion 2037-08-05 (estimated)
Study Completion 2037-12-01 (estimated)
Updated on ClinicalTrials.gov 2025-01-13